Fresenius SE & Co KGaA (FREG.DE)
46.68EUR
4:35pm GMT
€-0.49 (-1.04%)
€47.17
€47.01
€47.40
€46.29
1,643,129
2,264,599
€71.36
€38.28
Latest Key Developments (Source: Significant Developments)
Fresenius says rules out meaningful restructuring charges in 2019
Dec 7 (Reuters) - Fresenius SE & Co KGaA
Fresenius SE & Co Expects Mid-Single Digit Organic Growth In The Medium-Term, After Strong Investment Year 2019
Dec 6 (Reuters) - :DGAP-ADHOC: FRESENIUS SE & CO. KGAA: FRESENIUS EXPECTS MID-SINGLE DIGIT ORGANIC GROWTH IN THE MEDIUM-TERM, AFTER STRONG INVESTMENT YEAR 2019.GIVEN ITS CURRENT EXPECTATIONS FOR FY 2018 AND FY 2019, FRESENIUS NOW BELIEVES ITS AMBITIOUS GROUP TARGETS FOR 2020 WILL NOT BE MET.FROM 2020 ONWARDS, FRESENIUS NOW EXPECTS SUSTAINABLE ORGANIC GROUP SALES GROWTH IN MID-SINGLE DIGITS.FRESENIUS EXPECTS MID-SINGLE DIGIT ORGANIC SALES GROWTH FOR FY 2019.FY 2019 GROUP NET INCOME IS EXPECTED TO BE BROADLY STABLE OVER FY 2018.FROM 2020 ONWARDS GROUP NET INCOME IS EXPECTED TO GROW ORGANICALLY SLIGHTLY FASTER THAN SALES.UPON FRESENIUS KABI'S BIOSIMILARS BUSINESS BREAKING EVEN, FRESENIUS EXPECTS AN ACCELERATION OF GROUP EARNINGS GROWTH. Full Article
Fresenius Kabi USA Issues Voluntary Nationwide Recall of Sodium Chloride Injection, USP, 0.9%
Nov 20 (Reuters) - Fresenius Kabi USA::FRESENIUS KABI ISSUES VOLUNTARY NATIONWIDE RECALL OF SODIUM CHLORIDE INJECTION, USP, 0.9% DUE TO PRODUCT LABELING INCORRECTLY STATING STOPPERS DO NOT CONTAIN LATEX.FRESENIUS KABI USA SAYS VOLUNTARILY RECALLING 163 LOTS OF SODIUM CHLORIDE INJECTION, USP, 0.9% 10 ML FILL IN A 10 ML VIAL & 20 ML FILL IN A 20 ML VIAL.FRESENIUS KABI USA SAYS TO DATE, CO HAS NOT RECEIVED ANY REPORTS OF ADVERSE EVENTS RELATED TO RECALL OF SODIUM CHLORIDE INJECTION, USP, 0.9%. Full Article
Fresenius Kabi Introduces Leukemia Drug Arsenic Trioxide Injection In 10 mg per 10 mL Vial
Oct 26 (Reuters) - Fresenius Kabi::FRESENIUS KABI SAYS ANNOUNCES IMMEDIATE AVAILABILITY IN U.S. OF ARSENIC TRIOXIDE INJECTION IN A 10 MG PER 10 ML VIAL PRESENTATION.FRESENIUS KABI SAYS ARSENIC TRIOXIDE INJECTION IS FIRST-TO-MARKET GENERIC OF TRISENOX INDICATED FOR RELAPSED/REFRACTORY ACUTE PROMYELOCYTIC LEUKEMIA. Full Article
Fresenius Says Simplist Palonosetron Hydrochloride Injection Available In The U.S
Oct 22 (Reuters) - Fresenius SE & Co KGaA
Akorn Appeals Fresenius Kabi Ruling
Oct 18 (Reuters) - Akorn Inc
Abbvie Announces Resolution Of Humira Patent Disputes With Fresenius Kabi
Oct 18 (Reuters) - AbbVie Inc
Fresenius Kabi Biosimilar Candidate Meets Primary Endpoints In Two Studies
Oct 9 (Reuters) - Fresenius SE & Co KGaA
Akorn Comments On Delaware Chancery Court Ruling
Oct 1 (Reuters) - Akorn Inc
Fresenius CEO Expects Akorn Matter To Be Resolved By Early 2019
July 31 (Reuters) - Fresenius Se
Downbeat Draghi curbs gains on European shares as tech shines
MILAN/LONDON European shares ended off highs on Thursday as a bounce in tech stocks after results from chipmaker STMicro was offset by late slide among banks following downbeat comments from ECB President Mario Draghi over the health of the region's economy.